| Aug 1 |
Biogen lifts profit forecast, signals progress in turnaround effort
|
| Aug 1 |
As sales climb, Biogen ‘convinced’ the worst is over for Leqembi
|
| Jul 31 |
Biogen Q2 2024 Earnings Preview
|
| Jul 31 |
Biogen, Beckman Coulter and Fujirebio partner to develop Alzheimer’s Tau blood test
|
| Jul 31 |
Alcyone Therapeutics Announces Continued Enrollment Approval from FDA of the PIERRE Pivotal IDE Clinical Study of the ThecaFlex DRx™ System for Administration of nusinersen
|
| Jul 31 |
Vertex’s pain drug gets speedy FDA review; Keytruda hits a sales milestone
|
| Jul 30 |
Biogen, Eisai present positive three-year use data for Leqembi
|
| Jul 30 |
New Clinical Data Demonstrates Three Years of Continuous Treatment with Dual-Acting LEQEMBI® (lecanemab-irmb) Continues to Significantly Benefit Early Alzheimer’s Disease Patients Presented at The Alzheimer’s Association International Conference (AAIC)...
|
| Jul 30 |
Watch These 5 Biotech Stocks for Q2 Earnings: Beat or Miss?
|
| Jul 30 |
Acadia Pharmaceuticals (ACAD) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
|
